Meiji Clarifies Media Reports

1. Date of Event: 115/07/06 2. Company Name: Alvogen Korea Co., Ltd. 3. Relationship with Company (Please specify 'Our Company' or 'Subsidiary'): Subsidiary 4. Cross-shareholding Ratio: Not applicable 5. Name of Media Outlet: China Times Business 6. Content of Report: Meiji (1795) has achieved another milestone in its oncology product strategy. Its wholly-owned subsidiary, Alvogen Korea, jointly announced with Shanghai Henlius that SERPLUMAR, an independently developed anti-PD-1 monoclonal antibody, has been approved by South Korea's Ministry of Food and Drug Safety (MFDS) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). This approval provides South Korean patients with a new immunotherapy option and further strengthens Meiji's positioning in the Asian oncology market. 7. Reason for Occurrence: Media report 8. Response Measures: SERPLUMAR (serplulimab) is a humanized anti-PD-1 monoclonal antibody independently developed by Henlius. As stated in Meiji Pharma's press release dated July 2, 115: 'Alvogen Korea, a wholly-owned subsidiary of Meiji Pharma (hereinafter "Meiji", Taiwan Stock Exchange code: 1795), and Shanghai Henlius Biotech Co., Ltd. (2696.HK, hereinafter "Henlius") today announced that SERPLUMAR (serplulimab) has been approved by South Korea's Ministry of Food and Drug Safety (MFDS) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). SERPLUMAR, developed independently by Henlius, will provide a new immuno-oncology treatment option for ES-SCLC patients in South Korea.' 9. Other Matters to be Clarified: None